JERSEY CITY, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today reported financial results for the year ended December 31,
JERSEY CITY, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 29 th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in Dana Point on Tuesday, March 14, 2017 at 5:30 p.m. PT.
JERSEY CITY, N.J., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will participate in the following upcoming investor conferences: Canaccord Genuity Rare Disease Conference at the InterContinental New York Barclay Hotel in
— Former Chief Operating Officer of Medivation adds broad experience in commercial, strategy, operations and business development — — SCYNEXIS to ramp up commercial preparatory and territorial licensing activities for its lead product, SCY-078 — JERSEY CITY, N.J., Jan.
— Regimen of intravenous (IV) formulation of SCY-078 successfully identified and characterized to support subsequent studies — — Long-term toxicology studies completed, confirming favorable safety profile of oral SCY-078 — JERSEY CITY, N.J., Dec.
JERSEY CITY, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX), a pharmaceutical company developing novel anti-infectives to address unmet therapeutic needs, today announced that the Company will participate in the Guggenheim Securities 4 th Annual Boston
-- Positive Results From Multiple Studies Provide Clear Evidence of Clinical Antifungal Activity and Favorable Safety Profile of SCY-078 -- -- Company is Well Positioned and Capitalized to Accelerate and Expand Clinical Development of SCY-078 in Multiple Indications -- JERSEY CITY,
SCY-078 demonstrates a low potential for certain drug-drug interactions — a relevant differentiator versus the azoles, the leading antifungal class — providing an opportunity for favorable labeling Significant step forward to further de-risk the ongoing development program of SCY-078
Study Results Confirm Overall Antifungal Activity of Oral SCY-078 in Patients with Candida Infections Well-Tolerated and Active Oral Dose of SCY-078 Identified for Invasive Candidiasis Patients Evidence of Efficacy and Lower Relapse Rates versus Standard of Care in VVC Patients Strong Cash Position